Sherpa Healthcare Partners, a healthcare venture capital (VC) firm in China, has led a $80-million Series B round of financing for US-based life sciences startup Alamar Biosciences to fund its ambitions in transforming proteomics for the early detection of cancer and other diseases.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
